4/25
11:44 am
lqda
Earnings Preview: Liquidia Technologies, Inc. (LQDA) Q1 Earnings Expected to Decline [Yahoo! Finance]
Low
Report
Earnings Preview: Liquidia Technologies, Inc. (LQDA) Q1 Earnings Expected to Decline [Yahoo! Finance]
4/24
06:47 am
lqda
When Will Liquidia Corporation (NASDAQ:LQDA) Become Profitable? [Yahoo! Finance]
Medium
Report
When Will Liquidia Corporation (NASDAQ:LQDA) Become Profitable? [Yahoo! Finance]
4/10
08:05 am
lqda
Liquidia Co. (NASDAQ: LQDA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
Medium
Report
Liquidia Co. (NASDAQ: LQDA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
4/3
01:21 pm
lqda
Liquidia Corporation (NASDAQ:LQDA) has caught the attention of institutional investors who hold a sizeable 38% stake [Yahoo! Finance]
Low
Report
Liquidia Corporation (NASDAQ:LQDA) has caught the attention of institutional investors who hold a sizeable 38% stake [Yahoo! Finance]
4/2
09:29 am
lqda
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
Low
Report
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
4/2
09:00 am
lqda
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
Low
Report
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
4/1
11:03 am
lqda
Liquidia Co. (NASDAQ: LQDA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
Low
Report
Liquidia Co. (NASDAQ: LQDA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
4/1
06:00 am
lqda
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
Medium
Report
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
3/28
04:34 pm
lqda
Liquidia gains after court win in patent dispute with United Therapeutics [Seeking Alpha]
Medium
Report
Liquidia gains after court win in patent dispute with United Therapeutics [Seeking Alpha]
3/18
03:11 pm
lqda
Liquidia Co. (NASDAQ: LQDA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
Low
Report
Liquidia Co. (NASDAQ: LQDA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
3/18
03:05 pm
lqda
Liquidia Co. (NASDAQ: LQDA) had its price target raised by analysts at HC Wainwright from $16.00 to $32.00. They now have a "buy" rating on the stock.
Low
Report
Liquidia Co. (NASDAQ: LQDA) had its price target raised by analysts at HC Wainwright from $16.00 to $32.00. They now have a "buy" rating on the stock.
3/16
02:57 pm
lqda
Liquidia Corporation (NASDAQ:LQDA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Liquidia Corporation (NASDAQ:LQDA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/14
06:51 am
lqda
Liquidia Full Year 2023 Earnings: Misses Expectations [Yahoo! Finance]
Low
Report
Liquidia Full Year 2023 Earnings: Misses Expectations [Yahoo! Finance]
3/13
06:00 am
lqda
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
Medium
Report
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
3/6
06:46 am
lqda
Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024 [Yahoo! Finance]
Low
Report
Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024 [Yahoo! Finance]
3/6
06:30 am
lqda
Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024
Low
Report
Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024
2/21
03:26 pm
lqda
United Therapeutics' Challenges FDA Over Liquidia's Drug Approval Process, Clocks Strong Q4 Earnings [Yahoo! Finance]
Low
Report
United Therapeutics' Challenges FDA Over Liquidia's Drug Approval Process, Clocks Strong Q4 Earnings [Yahoo! Finance]
2/21
02:23 pm
lqda
Liquidia Co. (NASDAQ: LQDA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
Low
Report
Liquidia Co. (NASDAQ: LQDA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
2/21
06:57 am
lqda
UPDATE 1-United Therapeutics files litigation with FDA over rival Liquidia's drug application [Yahoo! Finance]
Low
Report
UPDATE 1-United Therapeutics files litigation with FDA over rival Liquidia's drug application [Yahoo! Finance]
2/21
06:16 am
lqda
United Therapeutics starts litigation with FDA for allowing Liquidia's drug application [Yahoo! Finance]
Low
Report
United Therapeutics starts litigation with FDA for allowing Liquidia's drug application [Yahoo! Finance]
2/21
06:13 am
lqda
United Therapeutics starts litigation with FDA for allowing Liquidia's drug application [Reuters]
Low
Report
United Therapeutics starts litigation with FDA for allowing Liquidia's drug application [Reuters]
2/15
12:10 pm
lqda
Liquidia Corporation: A Complicated Tale [Seeking Alpha]
Low
Report
Liquidia Corporation: A Complicated Tale [Seeking Alpha]
2/14
08:09 pm
lqda
MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation [Seeking Alpha]
Low
Report
MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation [Seeking Alpha]
2/12
10:51 pm
lqda
Liquidia Continues To Expand Their Growth Vs. MannKind's Growth In Share Prices [Seeking Alpha]
Medium
Report
Liquidia Continues To Expand Their Growth Vs. MannKind's Growth In Share Prices [Seeking Alpha]
1/30
06:40 am
lqda
Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress [Yahoo! Finance]
Medium
Report
Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress [Yahoo! Finance]